Initial Resuscitation for Acute Kidney Injury in Cirrhosis
Initial Resuscitation for Acute Kidney Injury in Patients With Cirrhosis: A Pilot Randomized Trial Using a Volume Assessment Guidance Algorithm
Massachusetts General Hospital
50 participants
Sep 12, 2024
INTERVENTIONAL
Conditions
Summary
The goal of this interventional study is to evaluate two strategies for how to provide intravenous (IV) fluids for treating patients with acute kidney injury (AKI) in cirrhosis. The main question it aims to answer is: what is the safety, efficacy, and feasibility of providing a recommendation to use a Volume Assessment Guidance Algorithm (VAGA) or give standard of care doses of IV albumin? Patients will be randomly assigned where their treating teams will receive a VAGA-based recommendation or a standard of care IV albumin recommendation.
Eligibility
Inclusion Criteria5
- Adult age 18 years or greater
- Signed informed consent form (ICF) by any subject capable of giving consent, or, when the subject is not capable of giving consent, by their legally authorized representatives prior to initiation of any study procedures.
- Admitted to the hospital
- Diagnosis of decompensated cirrhosis (either prior to admission or new diagnosis on admission).
- Presence of acute kidney injury (AKI) as defined by International Club of Ascites (ICA) criteria, defined as SCr increase of ≥0.3 mg/dL within 48 hours or ≥50% increase from baseline which is known or presumed to have occurred within the prior 7 days.
Exclusion Criteria14
- Requiring \>2 liters (L) supplemental oxygen at the time of screening.
- In shock requiring vasopressors (vasoconstrictors for the treatment of AKI such as terlipressin, midodrine, and octreotide are allowed).
- Allergy or other contraindication to IV albumin administration.
- Death, liver transplant, or renal replacement therapy (RRT) expected within 48 hours.
- Patient and/or legally authorized representative unable to provide informed consent.
- Hepatic encephalopathy grade 3 or 4 at the time of screening.
- Already received \>200 g albumin during admission at the time of screening.
- Severe, active bleeding requiring 3 or more units of red blood cell transfusion in the 48 hours prior to screening.
- Admission to the intensive care unit at the time of screening.
- Mechanical ventilation at the time of screening.
- Presence of New York Heart Association (NYHA) class 3-4 symptoms of congestive heart failure at the time of screening.
- History of prior liver or kidney transplant.
- Pregnant or nursing status
- Any condition, in the opinion of the investigator, that could confound or interfere with the safe completion of study activities.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Treatment teams are encouraged not to administer any additional fluids
Treatment teams are encouraged to administer crystalloid. Amount of resuscitative fluid will be determined by treatment team's clinical assessments and usual standards of care
Treatment teams are encouraged to administer colloid. Amount of resuscitative fluid will be determined by treatment team's clinical assessments and usual standards of care
Treatment teams are encouraged to administer 1 g/kg/d IV albumin (maximum 100 g/day) over 2 days
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06525623